Yes, you can safely add a single dose of fosfomycin now
A single dose of fosfomycin (3g) can be administered now without concern for drug interactions or safety issues related to the tobramycin received 5 days ago. There are no clinically significant drug interactions between these two antibiotics, and sufficient time has elapsed since the tobramycin administration.
Key Clinical Considerations
Drug Interaction Profile
Fosfomycin has minimal drug interactions. The FDA label specifically identifies only two relevant interactions 1:
- Metoclopramide (and drugs that increase GI motility) - lowers fosfomycin serum and urinary concentrations
- Cimetidine - does NOT affect fosfomycin pharmacokinetics
Tobramycin is not listed as an interacting drug, and there is no pharmacological basis for concern about combining these agents.
Temporal Separation
Five days provides more than adequate separation:
- Tobramycin has an elimination half-life of approximately 1.8-3 hours in most patients 2, 3
- After 5 days (120 hours), tobramycin would be essentially completely eliminated from the body (>40 half-lives)
- Fosfomycin is given as a single dose and is not metabolized, being excreted unchanged in urine 4
Clinical Context for Fosfomycin Use
Fosfomycin is appropriate for:
Uncomplicated cystitis in women:
- Single 3g dose is a first-line option 5, 6, 7
- Clinical efficacy ~91%, microbiological eradication ~80% 5
- Maintains urinary concentrations >128 mg/L for 24-48 hours 4
Important caveats:
- Fosfomycin has inferior efficacy compared to nitrofurantoin or trimethoprim-sulfamethoxazole for uncomplicated cystitis 5
- Not recommended for pyelonephritis - insufficient data for oral fosfomycin in upper tract infections 8
- Do not use repeated daily doses - this does not improve outcomes and increases adverse events 1
Synergistic Potential
Research actually suggests potential synergy between fosfomycin and aminoglycosides (like tobramycin):
- Against Pseudomonas aeruginosa biofilms, fosfomycin/tobramycin combinations showed enhanced bacterial killing 9, 10
- However, combinations did not prevent emergence of fosfomycin resistance 10
Safety Profile
- Common side effects: diarrhea, nausea, headache 5
- No nephrotoxicity or ototoxicity concerns (unlike tobramycin) 1
- Pregnancy category B 1
- Well-tolerated with minimal adverse effects in clinical practice 7, 4
The clinical decision should focus on whether fosfomycin is the appropriate antibiotic for the specific infection being treated, not on any interaction with prior tobramycin use.